Lenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone in Relapse and Refractory DLBCL
Status:
Unknown status
Trial end date:
2019-12-31
Target enrollment:
Participant gender:
Summary
Previous study showed that Lenalidomide or R-GDP could achieve response in Relapse and
Refractory DLBCL.The investigators therefore design this phase I study to investigate the
safety and efficacy of R2-GOD in relapsed diffuse large-cell lymphoma.
Phase:
Phase 1
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University